Augmented antitumour effects of combination therapy with TNP-470 and chemoimmunotherapy in mice

Journal of Cancer Research and Clinical Oncology

Volumn 128, Issue 8, 2002, Pages 433-442

  Dabrowska Iwanicka, Anna ^a,b   Olszewska, Dominika ^a   Jalili, Ahmad ^a   Makowski, Marcin ^a   Grzela, Tomasz ^a   Marczak, Maria ^a   Hoser, Grazyna ^c   Giermasz, Adam ^a   Golab, Jakub ^a   Jakóbisiak, Marek ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Antiangiogenic agents; IL 12; Melanoma; Mice; TNP 470; Tumour therapy

Indexed keywords

CISPLATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GAMMA INTERFERON; INTERLEUKIN 12;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL LINE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; INOCULATION; MELANOMA; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR MODEL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BENZOTHIAZOLES; BLOTTING, WESTERN; CELL DIVISION; CISPLATIN; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYCLOHEXANES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-12; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; NEOVASCULARIZATION, PATHOLOGIC; SESQUITERPENES; TETRAZOLIUM SALTS; THIAZOLES; TOLUENE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036037447     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-002-0356-z     Document Type: Article

References (28)

1. Criteria for analyzing interactions between biologically active agents
2. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer
3. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
4. TNP-470 (AGM-1470): Mechanisms of action and early clinical development
5. Anti-angiogenic agents: Clinical trial design and therapies in development
6. What is the evidence that tumours are angiogenesis-dependent?
7. Antitumour effects of interleukin-12 in pre-clinical and early clinical studies
8. G-CSF prevents the suppression of bone marrow heamatopoiesis induced by IL-12 and augments its antitumour activity in a melanoma model in mice
9. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
10. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models
11. IFN-gamma induction of p21(WAF1) is required for cell cycle inhibition and suppression of apoptosis
12. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
13. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy
14. Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor α in mice
15. p53, the cellular gatekeeper for growth and division
16. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage
17. Synergistic effect of retinoids and interferon-γ on tumour-induced angiogenesis: Anti-angiogenic effects on HPV-harboring tumour-cell lines
18. TNP-470 and recombinant human interferon-alpha2a inhibit angiogenesis synergistically
19. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF/CIP1/SDI1 induced by cisplatin and paclitaxel
20. Synergistic effect of the angiogenesis inhibitor TNP-470 and tumour necrosis factor (TNF) on Bomirski Ab melanoma in hamsters
21. Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression
22. Antiangiogenic therapy of transgenic mice impairs de novo tumour growth
23. Angiogenesis inhibitor TNP-470: Cytotoxic effects on human neoplastic cell lines
24. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
25. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma
26. Inhibition of angiogenesis in vivo by interleukin 12
27. The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest
28. Immunomodulation by anticancer chemotherapy: More is not always better